Results

eNauka >  Results >  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Group
Title: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Group
Authors : M. Miguel; F. Holmes; B. Ejlertsen; S. Delaloge; B. Moy; H. Iwata; G. von Minckwitz; S. Chia; J. Mansi; C. Barrios;
Tomašević, Zorica I.  ; M. Gnant...et al.; ExteNET Study Group;
Issue Date: 2017
Publication: Lancet Oncology
ISSN: 1470-2045 Lancet Oncology Search Idenfier
Publisher: London : Lancet Pub. Group
Type: Article
Collation: vol. 18 br. 12 str. 1688-1700
DOI: 10.1016/S1470-2045(17)30717-9
WoS-ID: 000417001900046
Scopus-ID: 2-s2.0-85035115011
PMID: 29146401
URI: https://enauka.gov.rs/handle/123456789/417439
URL: https://pubmed.ncbi.nlm.nih.gov/29146401/
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30717-9/fulltext
Metadata source: Migrirano iz RIS podataka
M-category: 
21a+M21a+

547
SCOPUSTM
292
PubMed CentralTM
344
OpenCitations
476
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.